Company intelligence
iECURE, inc.
Pioneering Variant-Agnostic In Vivo Targeted Gene Insertion to Treat Rare Disorders
About iECURE, inc.
iECURE is a clinical-stage genome editing company dedicated to transforming the lives of patients with devastating neurometabolic disorders by harnessing new advancements in genetic medicine. Our variant-agnostic, in vivo targeted gene insertion approach aims to restore the function of a missing or dysfunctional gene, regardless of variant, by inserting a functional copy to enable durable gene expression and the potential for long-term benefit. We’re advancing a pipeline of genetic medicines, led by ECUR-506, an investigational therapy in clinical development for neonatal-onset ornithine transcarbamylase (OTC) deficiency. Headquartered in Blue Bell, Pennsylvania, iECURE is proud to be recognized as one of the Philadelphia Business Journal’s “Best Places to Work” for three consecutive years and as one of Fierce Biotech’s “Fierce 15” in 2024.
Verified activity
Signals from iECURE, inc.
2 published signals
Presence & Recognition
iECURE, inc. participated in the SSIEM2026 event in Helsinki, where the theme Next Generation Metabolic Medicine brought together clinicians, researchers, geneticists, dietitians, patients, and advocates.
Reported by iECURE, inc.
Presence & Recognition
iECURE, inc. will participate in the upcoming 2026 Cantor Fitzgerald Global Healthcare Conference and Oppenheimer & Co. Inc. Private Life Sciences Showcase
Reported by iECURE, inc.